Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03264027
Other study ID # kaiserargongjanastomosis
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 6, 2017
Est. completion date January 12, 2020

Study information

Verified date August 2022
Source Kaiser Clinic and Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this randomized clinical trial is to compare pain levels during and after insufflation with carbon dioxide or in subjects that will undergo endoscopic fulguration with argon to reduce the diameter of the gastrojejunal anastomosis. The investigators hypothesize that carbon dioxide will be superior in causing less pain and leading to less discomfort.


Description:

Laparoscopic gastric bypass surgery is one of the strategies oriented towards weight reduction in obese patients. Although in the short term it has a high degree of success, weight regain is common in the long term, in part due to the dilatation of the anastomosis that allows food to pass without barriers and hinders the purpose of bypass surgery. Fulguration with argon is an endoscopic technique that reduces the diameter of the anastomosis, offering resistance to food passage and improving patient outcomes. Although carbon dioxide is the current standard for laparoscopic surgery, its use for fulguration with argon as compared to ambient air has not been investigated in the setting of the stenosis of a dilated anastomosis following gastric bypass surgery. stenosis. Therefore, to investigate pain during and after this procedure, investigators will conduct a randomized clinical trial comparing carbon dioxide and ambient air. The secondary aims will be to measure the diameter of the gastrojejunal anastomosis during three endoscopic sessions and in a final control examination eight weeks after the third session; to determine whether the patient loses weight or not by the final control objective after three sessions of endoscopic fulguration with argon; to analyze if the method employed is able to reduce body weight to the minimum weight achieved after bariatric surgery;and to investigate whether there is a correlation between the percentage reduction in anastomotic diameter and the percentage loss of regained weight.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date January 12, 2020
Est. primary completion date January 12, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Regain of at least 10.0% of the minimum weight reached after the gastric bypass; - Ability to understand study procedures; - Signed the informed written consent form; - Possible to complete all the stages of the study. Exclusion Criteria: - Presence of very tight restrictive ring preventing the advancement of the endoscopy device; - Stenosis of the anastomosis preventing the progression of the endoscopy device before the end of the three endoscopic sessions; - History of liver diseases such as cirrhosis or chronic active hepatitis; - Patients who required anticoagulant therapy with the exception of antiplatelet agents; - Pregnant women or those intending to become pregnant within 12 months after fulguration with argon; - Participant in another ongoing clinical research; - Recent history of neoplasia (less than 5 years); - Alcoholism or drug use; - HIV positive; - Unbalanced or uncontrollable psychiatric disorders; - Anemia or severe nutritional deficiencies; - Allergy to anesthetic compounds; - Impossibility to return within defined periods for consultations and endoscopic sessions of fulguration with argon; - Inability to follow nutritional guidelines after each endoscopic session; - Inability to understand study procedures;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Carbon dioxide
Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
Ambient air
Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
Argon fulguration
The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).

Locations

Country Name City State
Brazil Kaiser Clinic and Day Hospital São José do Rio Prêto Sao Paolo

Sponsors (1)

Lead Sponsor Collaborator
Kaiser Clinic and Hospital

Country where clinical trial is conducted

Brazil, 

References & Publications (1)

Baretta GA, Alhinho HC, Matias JE, Marchesini JB, de Lima JH, Empinotti C, Campos JM. Argon plasma coagulation of gastrojejunal anastomosis for weight regain after gastric bypass. Obes Surg. 2015 Jan;25(1):72-9. doi: 10.1007/s11695-014-1363-2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Pain Visual Analogue Scale A visual scale to assess self-reported pain going from 0 to 10. Before surgery, and after eight weeks of the first endoscopic session. The outcome will be the substraction of the initial value and the final value of pain.
Secondary Change in diameter of the gastrojejunal anastomosis Analysis and measurement in millimeters of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). Before surgery, and after eight weeks of the first endoscopic session.
Secondary Weight reduction The final weight measured in kilograms after eight weeks of the initial surgery will be subtracted from the weight at the start of the trial Before surgery, and after eight weeks of the first endoscopic session.
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2